Re-inventing a better wheel? Serplulimab for squamous cell lung cancer

Derek De-Rui Huang; James Chih-Hsin Yang

doi:10.1016/j.ccell.2024.01.004

Re-inventing a better wheel? Serplulimab for squamous cell lung cancer

Cancer Cell. 2024 Feb 12;42(2):172-174. doi: 10.1016/j.ccell.2024.01.004.

Authors

Derek De-Rui Huang¹, James Chih-Hsin Yang²

Affiliations

¹ Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
² Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: chihyang@ntu.edu.tw.

PMID: 38350419
DOI: 10.1016/j.ccell.2024.01.004

Abstract

Immune checkpoint inhibitors have reshaped the treatment landscape of non-small cell lung cancer (NSCLC). However, chemoimmunotherapy trials dedicated to squamous NSCLC are limited. In this issue of Cancer Cell, Zhou et al. demonstrate serplulimab plus chemotherapy as an effective first-line regimen to treat patients with advanced squamous NSCLC.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Squamous Cell* / drug therapy
Epithelial Cells
Humans
Immune Checkpoint Inhibitors / therapeutic use
Lung Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors
Antibodies, Monoclonal